- Home
- UUU vs PLUR Comparison
UUU vs PLUR Comparison
Compare UUU & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UUU | PLUR |
|---|---|---|
| Founded | 1969 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4M | 25.5M |
| IPO Year | 2025 | 2001 |
Fundamental Metrics
Financial Performance| Metric | UUU | PLUR |
|---|---|---|
| Price | $5.27 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 31.7K | 12.3K |
| Earning Date | 02-19-2026 | 05-08-2026 |
| Dividend Yield | ★ 16.75% | N/A |
| EPS Growth | ★ 229.41 | 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $23,563,554.00 | $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 18.39 | ★ 309.82 |
| 52 Week Low | $2.82 | $2.00 |
| 52 Week High | $8.27 | $5.96 |
Technical Indicators
Market Signals| Indicator | UUU | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 30.02 | 27.87 |
| Support Level | $4.07 | N/A |
| Resistance Level | $6.35 | $2.58 |
| Average True Range (ATR) | 0.55 | 0.13 |
| MACD | -0.22 | 0.01 |
| Stochastic Oscillator | 0.40 | 3.51 |
Price Performance
Historical ComparisonAbout UUU Universal Security Instruments Inc.
Universal Safety Products Inc is a U.S.-based importer and distributor of home safety devices such as ventilation fans and ground fault circuit interrupters.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.